Keeley-Teton Advisors’s AbbVie ABBV Stock Holding History

Keeley-Teton Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$410K	Hold	1,955	–	–	0.05%	311
2024 Q4	$347K	Hold	1,955	–	–	0.04%	331
2024 Q3	$386K	Buy	1,955 +1	+0.1%	+$187	0.04%	328
2024 Q2	$335K	Sell	1,954 -1	-0.1%	-$166	0.04%	311
2024 Q1	$356K	Sell	1,955 -440	-18%	-$75.8K	0.04%	310
2023 Q4	$371K	Sell	2,395 -242	-9%	-$35.3K	0.05%	310
2023 Q3	$393K	Hold	2,637	–	–	0.06%	289
2023 Q2	$355K	Sell	2,637 -5,495	-68%	-$806K	0.05%	308
2023 Q1	$1.3M	Sell	8,132 -59	-0.7%	-$9.02K	0.16%	177
2022 Q4	$1.32M	Buy	8,191 +380	+5%	+$58.3K	0.16%	173
2022 Q3	$1.05M	Sell	7,811 -345	-4%	-$49.5K	0.14%	181
2022 Q2	$1.25M	Hold	8,156	–	–	0.16%	186
2022 Q1	$1.32M	Sell	8,156 -57	-0.7%	-$8.28K	0.14%	206
2021 Q4	$1.11M	Hold	8,213	–	–	0.12%	219
2021 Q3	$886K	Buy	+8,213	New	+$938K	0.1%	236
2021 Q2	–	Sell	-8,447	Closed	-$914K	–	267
2021 Q1	$914K	Sell	8,447 -140	-2%	-$15K	0.1%	228
2020 Q4	$920K	Sell	8,587 -53	-0.6%	-$5.09K	0.12%	178
2020 Q3	$757K	Sell	8,640 -13	-0.2%	-$1.22K	0.12%	172
2020 Q2	$850K	Buy	+8,653	New	+$762K	0.13%	169

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Keeley-Teton Advisors's ABBV Position: Q1 2025 in Review

Keeley-Teton Advisors held its AbbVie (ABBV) position steady in Q1 2025 at 1,955 shares worth $410K. The position accounts for 0.05% of the portfolio, ranked #311.

Keeley-Teton Advisors first reported a position in ABBV in Q2 2020 and has held it in 19 quarters since. The position peaked at $1.32M in Q4 2022. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

Keeley-Teton Advisors held 1,955 shares of AbbVie worth $410K as of Q1 2025.
Keeley-Teton Advisors left its AbbVie share count unchanged in Q1 2025.
AbbVie made up 0.05% of Keeley-Teton Advisors's portfolio in Q1 2025, its #311 holding.
Keeley-Teton Advisors first reported a position in AbbVie in Q2 2020 and has held it in 19 quarters since.
Keeley-Teton Advisors's AbbVie position peaked at $1.32M in Q4 2022.
3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Keeley-Teton Advisors's 13F filing for Q1 2025, filed 14 May 2025.